Pancreatic Cancer Research

ResearcherAalborg University HospitalActive in the last 2 years

Oskar Franklin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3777-6887; OpenAlex author ID A5022276318. Sources: OpenAlex.

Their work

Papers
42 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
98
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 9 papers · 2025: 4 papers · 2026: 15 papers

Papers 42

  1. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. First author DOI 10.1016/j.hpb.2025.10.004↗
  2. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Co-author DOI 10.1016/j.hpb.2026.04.451↗
  3. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.12.007↗
  4. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  5. Rapid autofluorescence based 3D optical imaging of the pancreatic cancer milieu at mesoscopic scale - stain-free volumetric segmentation. Last author DOI 10.1038/s41598-026-54433-z↗
  6. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  7. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  8. Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery With Venous Resection and Reconstruction: Timing, Incidence, and Risk Factors. Co-author DOI 10.1097/sla.0000000000006605↗
  9. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  10. Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18426-y↗
  11. ASO Visual Abstract: Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: a Comparative Study with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18603-z↗
  12. Novel Therapies Calls for Predictive Biomarkers: E2F7 in the Era of Perioperative S-1 for Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19631-z↗
  13. Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20191-5↗
  14. ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20304-0↗
  15. ASO Author Reflections: Understanding the Prognostic Role of Claudin 18.2 in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-026-20312-0↗
  16. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  17. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  18. Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. First author DOI 10.1097/sla.0000000000006690↗
  19. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuv… Co-author DOI 10.3892/ol.2024.14845↗
  20. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  21. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Co-author DOI 10.1016/j.pan.2024.11.011↗
  22. Multi-omics profiling to identify early plasma biomarkers in pre-diagnostic pancreatic ductal adenocarcinoma: a nested case-control study. Co-author DOI 10.1016/j.tranon.2024.102059↗
  23. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Co-author DOI 10.1097/sla.0000000000005925↗
  24. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-024-15157-4↗
  25. ASO Author Reflections: Is There a Role for Selective Adjuvant Radiotherapy in the Modern Era of Pancreatic Cancer Treatment? Co-author DOI 10.1245/s10434-024-15297-7↗
  26. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemothera… Co-author DOI 10.1245/s10434-024-15443-1↗
  27. Dynamic Anthropometrics in Pancreatic Cancer: Associations Between Body Composition Changes During Neoadjuvant Therapy and Survival Outcomes After Resection. Co-author DOI 10.1245/s10434-024-15975-6↗
  28. Metabolomics for early pancreatic cancer detection in plasma samples from a Swedish prospective population-based biobank. Co-author DOI 10.21037/jgo-23-930↗
  29. Portomesenteric venous contact ≤180° and overall survival in resectable head and body pancreatic adenocarcinoma treated with upfront surgery. Last author DOI 10.1016/j.ejso.2023.107097↗
  30. Extracellular Galectin 4 Drives Immune Evasion and Promotes T-cell Apoptosis in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-1088↗
  31. A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.3390/ijms232112969↗
  32. Hyperglycemia as a risk factor in pancreatic cancer: A nested case-control study using prediagnostic blood glucose levels. Last author DOI 10.1016/j.pan.2021.05.008↗
  33. Are Circulating Immune Cells a Determinant of Pancreatic Cancer Risk? A Prospective Study Using Epigenetic Cell Count Measures. Co-author DOI 10.1158/1055-9965.epi-21-0169↗
  34. Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples. Co-author DOI 10.3390/cancers13215321↗
  35. Mesoscopic 3D imaging of pancreatic cancer and Langerhans islets based on tissue autofluorescence. Co-author DOI 10.1038/s41598-020-74616-6↗
  36. A Case of Pancreatic Ductal Adenocarcinoma Arising From Atypical Flat Lesions. Co-author DOI 10.1097/mpa.0000000000001591↗
  37. Cancer Cell-Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2578↗
  38. Novel prognostic markers within the CD44-stromal ligand network in pancreatic cancer. Co-author DOI 10.1002/cjp2.122↗
  39. VEGF receptor-2/neuropilin 1 trans-complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Co-author DOI 10.1002/path.5141↗
  40. Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002124↗
  41. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-140430↗
  42. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. First author DOI 10.1186/1471-2407-13-154↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 16 shared papers, 2024–2026 · strength 3.88
  2. Marco Del Chiaro · 13 shared papers, 2024–2026 · strength 3.22
  3. Malin Sund · 16 shared papers, 2013–2026 · strength 2.39
  4. Toshitaka Sugawara · 10 shared papers, 2024–2026 · strength 2.22
  5. Daniel Öhlund · 14 shared papers, 2013–2026 · strength 2.12
  6. Hiroyuki Ishida · 8 shared papers, 2025–2026 · strength 2.10
  7. Thomas F. Stoop · 8 shared papers, 2025–2026 · strength 1.99
  8. Asif Halimi · 8 shared papers, 2023–2026 · strength 1.96
  9. Nils O. Elander · 4 shared papers, 2025–2026 · strength 1.00
  10. Hakon Blomstrand · 4 shared papers, 2025–2026 · strength 1.00
  11. Sara Jacobson · 4 shared papers, 2021–2026 · strength 0.88
  12. Andrii Khomiak · 3 shared papers, 2026 · strength 0.86
  13. Jun Yoshino · 3 shared papers, 2026 · strength 0.77
  14. Hanna E. Seppänen · 3 shared papers, 2026 · strength 0.77
  15. Caj H. Haglund · 3 shared papers, 2026 · strength 0.77
  16. Ella Kesti · 3 shared papers, 2026 · strength 0.77
  17. Ana Gleisner · 3 shared papers, 2024–2026 · strength 0.68
  18. Jun Ishida · 3 shared papers, 2024–2026 · strength 0.67
  19. Samuele Grandi · 3 shared papers, 2024–2026 · strength 0.67
  20. Adrienne Molnár · 3 shared papers, 2023–2026 · strength 0.66
  21. Marco Del Chiaro · 3 shared papers, 2024–2026 · strength 0.66
  22. Madeline B. Torres · 1 shared paper, 2026 · strength 0.63
  23. Robert J. Torphy · 3 shared papers, 2024 · strength 0.58
  24. Yuki Fujiwara · 2 shared papers, 2026 · strength 0.58
  25. Freek D. Daams · 3 shared papers, 2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.